Application of New Data in B-Cell Malignancies From ASCO and EHA 2020: Waldenström Macroglobulinemia, Mantle Cell Lymphoma, Hodgkin Lymphoma, and Diffuse Large B-Cell Lymphoma

In this episode, Jennifer R. Brown, MD, PhD, and John Allan, MD, discuss recent key clinical trial results in Waldenström macroglobulinemia, mantle cell lymphoma, Hodgkin lymphoma, and DLBCL presented at the 2020 annual meetings of the American Society of Clinical Oncology (ASCO) and the European Hematology Association (EHA). Studies include:ASPEN: Zanubrutinib vs ibrutinib in WMOASIS: Ibrutinib, venetoclax, and obinutuzumab in MCLGHSG HD17: PET-guided therapy in HLKEYNOTE-024: Pembrolizumab vs brentuximab in HLALEXANDER: AUTO3 in DLBCLPresenters:Jennifer R. Brown, MD, PhDAssociate Professor of MedicineDepartment of Hematologic MalignanciesDana-Farber Cancer InstituteHarvard Medical SchoolDirector, CLL CenterDepartment of Medical OncologyDana-Farber Cancer InstituteBoston, MassachusettsJohn Allan, MDAssistant Professor of MedicineDivision of Hematology and Medical OncologyWeill Cornell MedicineNew York, New YorkContent based on an online CME program supported by an educational grant from AstraZeneca.Link to full program: https://bit.ly/3aSfekM Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.